Literature DB >> 17388918

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

F Meier1, S Busch, K Lasithiotakis, D Kulms, C Garbe, E Maczey, M Herlyn, B Schittek.   

Abstract

BACKGROUND: In melanoma, several signalling pathways are constitutively activated. Among them, the RAS/RAF/MEK/ERK (MAPK) and PI3K/AKT (AKT) signalling pathways are activated through multiple mechanisms and appear to play a major role in melanoma development and progression.
OBJECTIVES: In this study, we examined whether targeting the MAPK and/or AKT signalling pathways would have therapeutic effects against melanoma.
METHODS: Using a panel of pharmacological inhibitors (BAY 43-9006, PD98059, U0126, wortmannin, LY294002) we inhibited the MAPK and AKT signalling pathways at different levels and evaluated the effects on growth, survival and invasion of melanoma cells in monolayer and organotypic skin culture.
RESULTS: Antiproliferative and proapoptotic effects of inhibitors alone in monolayer culture were disappointing and varied among the different cell lines. In contrast, combined targeting of the MAPK and AKT signalling pathways significantly inhibited growth and enhanced apoptosis in monolayer culture. To verify our data in a more physiological context we incorporated melanoma cells into regenerated human skin mimicking the microenvironment of human melanoma. Combinations of MAPK and AKT inhibitors completely suppressed invasive tumour growth of melanoma cells in regenerated human skin.
CONCLUSIONS: Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388918     DOI: 10.1111/j.1365-2133.2007.07821.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  48 in total

Review 1.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

Review 2.  Molecular targets in melanoma: time for 'ethnic personalization'.

Authors:  Shane Y Morita; Svetomir N Markovic
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

3.  PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.

Authors:  John T Lee; Ling Li; Patricia A Brafford; Marcia van den Eijnden; Molly B Halloran; Katrin Sproesser; Nikolas K Haass; Keiran S M Smalley; James Tsai; Gideon Bollag; Meenhard Herlyn
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

4.  HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.

Authors:  Sabine Damm; Petra Koefinger; Martina Stefan; Christian Wels; Gabor Mehes; Erika Richtig; Helmut Kerl; Marcus Otte; Helmut Schaider
Journal:  J Invest Dermatol       Date:  2010-04-01       Impact factor: 8.551

5.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

Review 6.  Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.

Authors:  S Wu; R K Singh
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

7.  MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma.

Authors:  Anupama Sahoo; Sanjaya K Sahoo; Piyush Joshi; Bongyong Lee; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2018-08-01       Impact factor: 8.551

8.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.

Authors:  Peng Hou; Dingxie Liu; Meiju Ji; Zhi Liu; James M Engles; Richard L Wahl; Mingzhao Xing
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

10.  Sorafenib in the treatment of advanced hepatocellular carcinoma.

Authors:  Ali Ben Mousa
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.